We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Assessment of Outcomes of Hepatitis C Treatment

Norberto C. Chavez-Tapia, MD, PhD1; Tonatiuh Barrientos-Gutierrez, MD, PhD2; Misael Uribe, MD, PhD1
[+] Author Affiliations
1Medica Sur Clinic and Foundation, Mexico City, Mexico
2Instituno Nacional de Salud Publica, Mexico City, Mexico
JAMA. 2014;312(23):2570-2571. doi:10.1001/jama.2014.14900.
Text Size: A A A
Published online


To the Editor The review by Dr Kohli and colleagues1 illustrated how hepatitis C virus (HCV) treatment has moved from the low efficacy and high complication rates observed with ribavirin plus interferon to the high sustained viral response (SVR) and rare complication rates observed with directly acting antivirals. Directly acting antivirals have been embraced by clinical guidelines2 and, given their comparable safety and efficacy, the discussion over which specific drug will be used in the near future has turned to availability and affordability. Yet in the midst of this discussion is a more clinically relevant question: now that SVR and safety seem assured, should the outcomes of HCV treatment be redefined?


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




December 17, 2014
Anita Kohli, MD; Shyam Kottilil, MD, PhD
1Department of Critical Care Medicine, National Institutes of Health, Bethesda, Maryland
2Institute of Human Virology, University of Maryland School of Medicine, Baltimore
JAMA. 2014;312(23):2571. doi:10.1001/jama.2014.14905.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...